VectivBio is a rare-disease biopharma led by CEO Luca Santarelli. The company was founded three years ago by Santarelli, a former Roche executive. It completed a public listing roughly a year ago. The article reports VectivBio has secured more than $100 million in new funding through a licensing pact and a loan. The article does not provide details on the company's specific product candidates, pipeline, operating metrics, or revenues. No counterparties or investors were named in the report. VectivBio AG is a Basel, Switzerland-based clinical-stage biotechnology company focused on developing transformational therapeutics for patients with serious rare diseases. Its lead investigational program is apraglutide, a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). Phase II studies of apraglutide demonstrated the potential for once-weekly dosing. The company closed a $110M crossover financing to support the Phase III program for apraglutide. Proceeds will also fund early commercialization activities and further development of the pipeline through business development initiatives. VectivBio is led by CEO Luca Santarelli, M.D., and pursues rare-disease programs with well-defined biology to deliver best-in-disease therapies. VectivBio is a clinical-stage biotechnology company formed to develop transformational medicines for patients with serious rare diseases. Its lead program, apraglutide, is a next-generation GLP-2 analog intended to increase the intestine's ability to absorb fluids and nutrients for patients with short bowel syndrome (SBS). The company notes an estimated 35,000 people with SBS in the U.S. and Europe and that severe patients require lifelong parenteral support. Apraglutide aims to reduce the burden of parenteral support by improving intestinal absorption. Topline results from two Phase 2 studies of apraglutide in SBS patients were expected by the end of the first quarter of 2020. The VectivBio executive team includes former Therachon leaders, aligning prior experience with the program's clinical development.

Total raised

$220M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Apr 2022